RTW Investments LP Purchases 56,457 Shares of Arbutus Biopharma Corporation (ABUS)

RTW Investments LP increased its position in shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) by 1.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,266,280 shares of the biopharmaceutical company’s stock after acquiring an additional 56,457 shares during the quarter. Arbutus Biopharma comprises approximately 5.7% of RTW Investments LP’s investment portfolio, making the stock its 8th biggest holding. RTW Investments LP owned about 9.57% of Arbutus Biopharma worth $32,651,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ABUS. Renaissance Technologies LLC lifted its stake in Arbutus Biopharma by 785.1% in the first quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 110,499 shares in the last quarter. Victory Capital Management Inc. bought a new position in Arbutus Biopharma in the second quarter valued at approximately $478,000. Vanguard Group Inc. lifted its stake in Arbutus Biopharma by 2.7% in the second quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 2,035 shares in the last quarter. Finally, OxFORD Asset Management LLP lifted its stake in Arbutus Biopharma by 89.9% in the second quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 39,436 shares in the last quarter. 60.00% of the stock is currently owned by institutional investors and hedge funds.

Shares of Arbutus Biopharma Corporation (NASDAQ ABUS) opened at $5.30 on Wednesday. The company has a current ratio of 11.03, a quick ratio of 11.03 and a debt-to-equity ratio of 0.08. Arbutus Biopharma Corporation has a 1 year low of $2.35 and a 1 year high of $8.25.

A number of research analysts have weighed in on the stock. BidaskClub lowered shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday. Wedbush reaffirmed an “outperform” rating and issued a $9.00 price target on shares of Arbutus Biopharma in a research note on Wednesday, September 20th. ValuEngine raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st. Leerink Swann reissued a “market perform” rating and issued a $5.00 price objective (up previously from $4.00) on shares of Arbutus Biopharma in a research report on Tuesday, November 7th. Finally, JMP Securities reissued an “outperform” rating and issued a $13.00 price objective (up previously from $12.00) on shares of Arbutus Biopharma in a research report on Wednesday, October 4th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. Arbutus Biopharma currently has a consensus rating of “Hold” and an average target price of $13.00.

In other news, insider Michael J. Sofia sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $8.00, for a total value of $80,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 10.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: “RTW Investments LP Purchases 56,457 Shares of Arbutus Biopharma Corporation (ABUS)” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/12/06/rtw-investments-lp-purchases-56457-shares-of-arbutus-biopharma-corporation-abus.html.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Want to see what other hedge funds are holding ABUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arbutus Biopharma Corporation (NASDAQ:ABUS).

Institutional Ownership by Quarter for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply